Customize your JAMA Network experience by selecting one or more topics from the list below.
More than 3.7 million infections and more than 140 000 deaths due to coronavirus disease 2019 (COVID-19) have occurred in the US in the past 6 months. As case counts continue to increase, robust vaccine development efforts unprecedented in scale and speed are being pursued. More than 130 COVID-19 vaccines are in preclinical development using a variety of established and new platforms, and 17 candidate vaccines are undergoing evaluation in clinical trials in the US, Europe, and China.1 The US government has invested in the development of 5 vaccines as part of Operation Warp Speed.2 On June 25, the Chinese government approved the first COVID-19 vaccine (Ad5-nCoV) for use in the military population.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Lee GM, Bell BP, Romero JR. The Advisory Committee on Immunization Practices and Its Role in the Pandemic Vaccine Response. JAMA. Published online July 22, 2020. doi:10.1001/jama.2020.13167
Create a personal account or sign in to: